Single Ascending Dose Study of ALA-1000

NCT04122755 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
59
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Alar Pharmaceuticals Inc.